(Q35734498)

10 August 2017

1 reference

title

Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease (English)

1 reference

10 August 2017

Gustav Paumgartner

1

1 reference

PubMed ID

15062194

10 August 2017

Ulrich Beuers

series ordinal

2

1 reference

10 August 2017

1 February 2004

1 reference

10 August 2017

Clinics in liver disease

1 reference

10 August 2017

8

1 reference

10 August 2017

67-81, vi

1 reference

10 August 2017

1

1 reference

Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up. A pilot study

10 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Pharmacology of ursodeoxycholic acid, an enterohepatic drug.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Improved liver tests and greater biliary enrichment with high dose ursodeoxycholic acid in early stage primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Molecular aspects of membrane stabilization by ursodeoxycholate [see comment]

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Effects of Ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKC alpha

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Tauroursodeoxycholic acid stimulates hepatocellular exocytosis and mobilizes extracellular Ca++ mechanisms defective in cholestasis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Tauroursodeoxycholic acid activates protein kinase C in isolated rat hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Hepatoprotection with tauroursodeoxycholate and beta muricholate against taurolithocholate induced cholestasis: involvement of signal transduction pathways

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Tauroursodeoxycholate prevents taurolithocholate-induced cholestasis and toxicity in rat liver

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Tauroursodesoxycholate-induced choleresis involves p38(MAPK) activation and translocation of the bile salt export pump in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Bile salt transporters: molecular characterization, function, and regulation

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Involvement of microtubules in the swelling-induced stimulation of transcellular taurocholate transport in perfused rat liver

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Mitogen-activated protein kinases mediate the stimulation of bile acid secretion by tauroursodeoxycholate in rat liver

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Ursodeoxycholic acid in cholestasis: potential mechanisms of action and therapeutic applications

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Characterization of the mouse bile salt export pump overexpressed in the baculovirus system

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Modulation of protein kinase C by taurolithocholic acid in isolated rat hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Taurolithocholic acid exerts cholestatic effects via phosphatidylinositol 3-kinase-dependent mechanisms in perfused rat livers and rat hepatocyte couplets

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Effects of tauroursodeoxycholic acid on cytosolic Ca2+ signals in isolated rat hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Stimulation of ATP secretion in the liver by therapeutic bile acids

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Assessment of biliary bicarbonate secretion in humans by positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Bile acid structure and selective modulation of murine hepatic cytochrome P450-linked enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Ursodeoxycholic acid (UDCA) prevents DCA effects on male mouse liver via up-regulation of CYP [correction of CXP] and preservation of BSEP activities

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Death receptor-mediated apoptosis and the liver

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Ursodeoxycholic acid cytoprotection: dancing with death receptors and survival pathways

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Effect of tauroursodeoxycholic acid on bile-acid-induced apoptosis and cytolysis in rat hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Effect of tauroursodeoxycholic acid on bile acid-induced apoptosis in primary human hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Ursodeoxycholic acid diminishes Fas-ligand-induced apoptosis in mouse hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Taurolithocholic acid-3 sulfate induces CD95 trafficking and apoptosis in a c-Jun N-terminal kinase-dependent manner

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Bile acids with differing hydrophilic-hydrophobic properties do not influence cytokine production by human monocytes and murine Kupffer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Ursodeoxycholic acid in the treatment of primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: effects on primary bile acids in babies and mothers

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis-related cholestatic liver disease. Results of a randomized study with 1-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900135-1

7 January 2021

10.1016/S1089-3261(03)00135-1

Identifiers

DOI

1 reference

10 August 2017

1 reference

PubMed ID

15062194